US EditionKye Pharmaceuticals gains Health Canada approval for Dyanavel XR
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Kye Pharmaceuticals gains Health Canada approval for Dyanavel XR
The approved drug is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults aged 18 years and above, as well as children between six to The post Kye Pharmaceuticals gains Health Canada approval for Dyanavel XR to treat ADHD appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
